Drug intelligence / Profile preview

SD-133

Development stage: Preclinical
Lead developer: Georgetown University
Modality: Small Molecules
Administration: Intraperitoneal

Overview

SD-133 is a drug-like small molecule inhibitor of cadherin-11 (CDH11) originally discovered and developed by researchers at Georgetown University. It binds specifically to the homodimerization interface (the W-binding pocket) of CDH11, preventing homophilic cell-cell adhesion. SD-133 has been investigated in preclinical models for its therapeutic potential in various cancers, including breast cancer, pancreatic cancer, and adenoid cystic carcinoma, where CDH11 overexpression drives tumor progression, invasion, and metastasis. Additionally, SD-133 has demonstrated nephroprotective properties in preclinical models of chronic kidney disease by reducing renal fibrosis and inhibiting the pro-fibrotic SMAD3 pathway.

Other names: 4-(2-phenylpyridin-3-yl)phenolCDH11-IN-1CDH-11-IN-1CDH 11-IN-1

Targets

CDH11 (Cadherin-11)

Beyond the preview

Go deeper on SD-133.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD-133.